These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Background Neuroleptic malignant syndrome (NMS) is a rare, severe, idiosyncratic adverse
reaction to antipsychotics. Second-generation antipsychotics (SGAs) were originally …

Objective: To review evidence for the treatment of neuroleptic malignant syndrome (NMS)
and to discuss how to rechallenge patients with neuroleptics when continued …

Numerous medical and psychiatric conditions can cause agitation; some of these causes
are life threatening. It is important to be able to differentiate between medical and …

Objective Neuroleptic malignant syndrome (NMS) is a potentially fatal, idiosyncratic reaction
to antipsychotics. Due to low incidence of NMS, research on risk factors of mortality …

Objective: To provide an overview of neuroleptic malignant syndrome (NMS) for the general
practitioner with the most up-to-date information on etiology, workup, and management …

Abstract Neuroleptic Malignant Syndrome (NMS) is a life threatening complication of
antipsychotic therapy. It is often assumed to be rare. Observations suggest that rather than …

Introduction Long-acting injectable antipsychotics (LAIs) are associated with multiple
positive outcomes in psychosis, but it is unclear whether LAIs are associated with worse …